Join Now

Utah Life Sciences News & Events

Rob Etherington

January 20, 2019

Rob Etherington is the President/CEO of Clene Nanomedicine, Inc., a Phase 2 clinical-stage biopharmaceutical pursuing drug therapies for Multiple Sclerosis, Parkinson’s Disease, and Amyotrophic Lateral Sclerosis (ALS, or Lou Gehrig’s Disease). Rob began his pharmaceutical career with a number of sales and marketing roles at Parke-Davis, a division of Pfizer, culminating in a Team Leader position over the drug Lipitor. He left Pfizer in 2000 to be the founding Director of Marketing during the IPO year of Swiss-based, Actelion Pharmaceutical, focused in cardiopulmonary disease. Actelion was the largest biopharm based in the EU until Johnson&Johnson Pharmaceuticals purchased Actelion. Rob was the first US commercial employee, leading U.S. commercial operations and serving as Chair of the US Commercial Strategic Team, with responsibility for five marketed drugs. As CEO of Clene Nanomedicine, Rob has raised ~$90M to-date to fund Clene’s drug development efforts. Clene’s first drug, CNM-Au8, is presently in multiple Phase 2 clinical human trials of remyelination for multiple sclerosis patients, and neurodegeneration for Parkinsons and ALS. A pipeline of other therapeutic nanotherapeutics are presently in preclinical development.